The altered glycan profile of APP in the brain and cerebrospinal fluid (CSF) of AD patients versus healthy controls (Påhlsson et al., 1992; Chun et al., 2017; Boix et al., 2020; Moran et al., 2021) has been reported. This evidence concerns the gene APP and Alzheimer disease.